180 related articles for article (PubMed ID: 10652623)
1. Microvessel density, proliferating activity, p53 and bcl-2 expression in in situ ductal carcinoma of the breast.
Zolota V; Gerokosta A; Melachrinou M; Kominea A; Aletra C; Scopa CD
Anticancer Res; 1999; 19(4B):3269-74. PubMed ID: 10652623
[TBL] [Abstract][Full Text] [Related]
2. Predicting the biologic behavior of ductal carcinoma in situ: an analysis of molecular markers.
Hieken TJ; Farolan M; D'Alessandro S; Velasco JM
Surgery; 2001 Oct; 130(4):593-600; discussion 600-1. PubMed ID: 11602889
[TBL] [Abstract][Full Text] [Related]
3. bcl-2 expression in the spectrum of preinvasive breast lesions.
Siziopikou KP; Prioleau JE; Harris JR; Schnitt SJ
Cancer; 1996 Feb; 77(3):499-506. PubMed ID: 8630957
[TBL] [Abstract][Full Text] [Related]
4. Ideas in pathology. Ductal carcinoma in situ of the breast: a proposal for a new simplified histological classification association between cellular proliferation and c-erbB-2 protein expression.
Poller DN; Silverstein MJ; Galea M; Locker AP; Elston CW; Blamey RW; Ellis IO
Mod Pathol; 1994 Feb; 7(2):257-62. PubMed ID: 7911998
[TBL] [Abstract][Full Text] [Related]
5. p53 mutations are confined to the comedo type ductal carcinoma in situ of the breast. Immunohistochemical and sequencing data.
O'Malley FP; Vnencak-Jones CL; Dupont WD; Parl F; Manning S; Page DL
Lab Invest; 1994 Jul; 71(1):67-72. PubMed ID: 8041120
[TBL] [Abstract][Full Text] [Related]
6. Similarity in expression of cell cycle proteins between in situ and invasive ductal breast lesions of same differentiation grade.
Mommers EC; Leonhart AM; Falix F; Michalides R; Meijer CJ; Baak JP; Diest PJ
J Pathol; 2001 Jul; 194(3):327-33. PubMed ID: 11439365
[TBL] [Abstract][Full Text] [Related]
7. Up-regulation of thymidine phosphorylase expression is associated with a discrete pattern of angiogenesis in ductal carcinomas in situ of the breast.
Engels K; Fox SB; Whitehouse RM; Gatter KC; Harris AL
J Pathol; 1997 Aug; 182(4):414-20. PubMed ID: 9306962
[TBL] [Abstract][Full Text] [Related]
8. Different proliferative patterns characterize different preinvasive breast lesions.
Viacava P; Naccarato AG; Bevilacqua G
J Pathol; 1999 Jul; 188(3):245-51. PubMed ID: 10419590
[TBL] [Abstract][Full Text] [Related]
9. Angiogenesis and inflammation in ductal carcinoma in situ of the breast.
Lee AH; Happerfield LC; Bobrow LG; Millis RR
J Pathol; 1997 Feb; 181(2):200-6. PubMed ID: 9120726
[TBL] [Abstract][Full Text] [Related]
10. Apocrine ductal carcinoma in situ of the breast: histologic classification and expression of biologic markers.
Leal C; Henrique R; Monteiro P; Lopes C; Bento MJ; De Sousa CP; Lopes P; Olson S; Silva MD; Page DL
Hum Pathol; 2001 May; 32(5):487-93. PubMed ID: 11381366
[TBL] [Abstract][Full Text] [Related]
11. Carcinoma in situ of the female breast. A clinico-pathological, immunohistological, and DNA ploidy study.
Ottesen GL
APMIS Suppl; 2003; (108):1-67. PubMed ID: 12874968
[TBL] [Abstract][Full Text] [Related]
12. Microvessel density and distribution in ductal carcinoma in situ of the breast.
Guidi AJ; Fischer L; Harris JR; Schnitt SJ
J Natl Cancer Inst; 1994 Apr; 86(8):614-9. PubMed ID: 7511693
[TBL] [Abstract][Full Text] [Related]
13. Expression of Her2/neu, steroid receptors (ER and PR), Ki67 and p53 in invasive mammary ductal carcinoma associated with ductal carcinoma In Situ (DCIS) Versus invasive breast cancer alone.
Mylonas I; Makovitzky J; Jeschke U; Briese V; Friese K; Gerber B
Anticancer Res; 2005; 25(3A):1719-23. PubMed ID: 16033090
[TBL] [Abstract][Full Text] [Related]
14. Angiogenic potential of ductal carcinoma in situ (DCIS) of human breast.
Vogl G; Dietze O; Hauser-Kronberger C
Histopathology; 2005 Dec; 47(6):617-24. PubMed ID: 16324200
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical analysis of p53 expression in primary breast carcinomas.
Naidu R; Yadav M; Nair S; Kutty KK
Anticancer Res; 1998; 18(1A):65-70. PubMed ID: 9568057
[TBL] [Abstract][Full Text] [Related]
16. Distinct angiogenic patterns are associated with high-grade in situ ductal carcinomas of the breast.
Engels K; Fox SB; Whitehouse RM; Gatter KC; Harris AL
J Pathol; 1997 Feb; 181(2):207-12. PubMed ID: 9120727
[TBL] [Abstract][Full Text] [Related]
17. Ductal carcinoma in situ of the breast and heparanase-1 expression: a molecular explanation for more aggressive subtypes.
Maxhimer JB; Pesce CE; Stewart RA; Gattuso P; Prinz RA; Xu X
J Am Coll Surg; 2005 Mar; 200(3):328-35. PubMed ID: 15737842
[TBL] [Abstract][Full Text] [Related]
18. p53 overexpression is a predictor of local recurrence after treatment for both in situ and invasive ductal carcinoma of the breast.
de Roos MA; de Bock GH; de Vries J; van der Vegt B; Wesseling J
J Surg Res; 2007 Jun; 140(1):109-14. PubMed ID: 17291532
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of p53, bcl-2, and Bax expression in early breast cancer.
Linjawi A; Kontogiannea M; Halwani F; Edwardes M; Meterissian S
J Am Coll Surg; 2004 Jan; 198(1):83-90. PubMed ID: 14698315
[TBL] [Abstract][Full Text] [Related]
20. Intraductal spread of invasive breast carcinoma has a positive correlation with c-erb B-2 overexpression and vascular invasion.
Jing X; Kakudo K; Murakami M; Nakamura Y; Nakamura M; Yokoi T; Yang Q; Oura S; Sakurai T
Cancer; 1999 Aug; 86(3):439-48. PubMed ID: 10430252
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
